Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial
Mariaelena Pierobon(George Mason University), Stephen P. Anthony, Angela Bellos(George Mason University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Elisa Baldelli(Abterra Biosciences (United States)), Sanja Avramovic(George Mason University), Julia Wulfkuhle(University of California, San Francisco), Linda Vocila(Translational Genomics Research Institute), Farrokh Alemi(George Mason University), Ariane Kemkes, Donald W. Northfelt(Mayo Clinic in Arizona), Janusz Wojtusiak(George Mason University), Rosa I. Gallagher(George Mason University), David W. Craig(City of Hope), Nicholas J. Robert(Tufts Medical Center), Amber Conrad(Translational Genomics Research Institute), John D. Carpten(City of Hope), Lance A. Liotta(George Mason University), Jessica Aldrich(Translational Genomics Research Institute), Shukmei Wong(Translational Genomics Research Institute), David Loesch(Caris Life Sciences (United States)), David Arguello(Caris Life Sciences (United States)), Bryant Dunetz(Side-Out Foundation), Kimberly A. Hodge(George Mason University), Mohammad Jahanzeb(Sylvester Comprehensive Cancer Center)
Cited by 14
Related Papers
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
|Journal of Clinical Investigation|2005|524
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
|Journal of Clinical Investigation|2005|508